Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRAF p.V600K status confers therapeutic sensitivity to Binimetinib, Encorafenib in patients with Melanoma.
Health Canada approved binimetinib, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
This statement is based on a regulatory approval from the Health Canada:
MEKTOVI (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.